Cyprotex Highlights - December 2020
2020 has been a challenging year for all, but for our last newsletter of the year we’d like to take the time to reflect on what we’ve managed to achieve, despite the difficulties!
Read on and click below to browse the highlights…
We started 2020 with the US FDA finalising the draft regulatory guidance for in vitro DDI studies. While very little changed between this update and the 2017 draft, there were still some things to watch out for, particularly for metabolism-mediated drug interactions and transporter inhibition studies.
The good news is that here at Cyprotex, we have done all the hard work for you by summarising the changes in our blog, and by updating our free ADME and DDI Guides. Read the blog to see our review on the FDA changes and download your free guides using the links below.
Cyprotex have led and contributed towards many publications released this year, covering a variety of topics such as mitochondrial respiratory inhibition, a review on DILI risk assessment strategy, and an update from our parent company, Evotec, discussing the use of transcriptomics in predictive toxicology.
Click on the links below to read all about our latest research:
With a total of 10 different webinars produced, we have really made it our mission this year to spread the word of science across the globe! We have made all of our webinars free to watch on demand, so why not catch up over the holidays?
Click on the links below to view the webinars:
In Vitro Approaches to Cosmetic Safety
Early Mitochondrial Screening in Drug Safety
Read the latest news from parent company, Evotec:
- Evotec publishes DDup 10: Transforming Toxicology Prediction via PanOmics.
- Evotec and Sartorius partner with Curexsys for scalable manufacturing of exosome-based therapeutics.
- Evotec achieves key milestones in targeted protein degradation with Bristol-Myers Squibb.
- Evotec & Alloy Therapeutics partner to expand Evotec's antibody discovery platform.
Telephone:
Europe: +44 (0)1625 505100
North America (East Coast): +1-888-297-7683
Email:
enquiries@cyprotex.com